Iterum Therapeutics (ITRM) Competitors $0.99 -0.01 (-0.91%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+0.92%) As of 06/13/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. ALMS, EDIT, ACRS, ENTA, SLN, RAPT, LFVN, MOLN, SLS, and SPROShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Alumis (ALMS), Editas Medicine (EDIT), Aclaris Therapeutics (ACRS), Enanta Pharmaceuticals (ENTA), Silence Therapeutics (SLN), RAPT Therapeutics (RAPT), LifeVantage (LFVN), Molecular Partners (MOLN), SELLAS Life Sciences Group (SLS), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors Alumis Editas Medicine Aclaris Therapeutics Enanta Pharmaceuticals Silence Therapeutics RAPT Therapeutics LifeVantage Molecular Partners SELLAS Life Sciences Group Spero Therapeutics Alumis (NASDAQ:ALMS) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Is ALMS or ITRM more profitable? Company Net Margins Return on Equity Return on Assets AlumisN/A N/A N/A Iterum Therapeutics N/A N/A -90.85% Does the MarketBeat Community prefer ALMS or ITRM? Iterum Therapeutics received 118 more outperform votes than Alumis when rated by MarketBeat users. However, 92.31% of users gave Alumis an outperform vote while only 63.11% of users gave Iterum Therapeutics an outperform vote. CompanyUnderperformOutperformAlumisOutperform Votes2492.31% Underperform Votes27.69%Iterum TherapeuticsOutperform Votes14263.11% Underperform Votes8336.89% Which has higher valuation and earnings, ALMS or ITRM? Alumis has higher revenue and earnings than Iterum Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumis$17.39M8.53N/AN/AN/AIterum TherapeuticsN/AN/A-$24.77M-$0.99-1.00 Does the media refer more to ALMS or ITRM? In the previous week, Alumis had 4 more articles in the media than Iterum Therapeutics. MarketBeat recorded 9 mentions for Alumis and 5 mentions for Iterum Therapeutics. Alumis' average media sentiment score of 1.10 beat Iterum Therapeutics' score of 0.78 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in ALMS or ITRM? 9.2% of Iterum Therapeutics shares are held by institutional investors. 9.2% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer ALMS or ITRM? Alumis currently has a consensus target price of $22.86, indicating a potential upside of 627.93%. Iterum Therapeutics has a consensus target price of $9.00, indicating a potential upside of 808.27%. Given Iterum Therapeutics' higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Alumis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAlumis beats Iterum Therapeutics on 8 of the 12 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.64M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.16%P/E Ratio-0.768.5026.7819.65Price / SalesN/A263.11404.49152.18Price / CashN/A65.8538.2534.64Price / Book-8.266.526.964.59Net Income-$24.77M$143.48M$3.23B$248.23M7 Day Performance2.15%-0.20%-1.24%-1.07%1 Month Performance5.46%11.63%8.34%3.35%1 Year Performance-13.83%3.21%33.30%13.77% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.4201 of 5 stars$0.99-0.9%$9.00+808.3%-15.3%$39.64MN/A-0.7610Analyst RevisionGap DownALMSAlumis2.8554 of 5 stars$3.43-4.5%$24.86+624.7%N/A$161.97M$17.39M0.00N/APositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionEDITEditas Medicine4.2314 of 5 stars$1.93+1.0%$5.36+177.9%-64.1%$161.57M$35.84M-0.75230Analyst RevisionGap UpACRSAclaris Therapeutics2.6591 of 5 stars$1.49-2.6%$9.71+552.0%+23.5%$161.34M$17.78M-2.87100Positive NewsENTAEnanta Pharmaceuticals3.7014 of 5 stars$7.50+0.4%$18.00+140.0%-44.2%$160.33M$64.46M-1.52160Positive NewsAnalyst DowngradeSLNSilence Therapeutics2.8439 of 5 stars$5.31-2.4%$33.83+537.2%-73.0%$158.93M$27.70M-3.38100News CoveragePositive NewsAnalyst ForecastRAPTRAPT Therapeutics3.8829 of 5 stars$1.20+2.6%$3.00+150.0%-70.1%$158.75M$1.53M-0.4380News CoverageStock SplitLFVNLifeVantage3.9842 of 5 stars$12.49-0.2%$30.50+144.2%+68.0%$157.22M$222.35M22.30260Positive NewsMOLNMolecular Partners2.8658 of 5 stars$3.89+2.2%$12.00+208.9%-34.9%$156.86M$2.23M-1.81180SLSSELLAS Life Sciences Group0.3671 of 5 stars$1.57-2.5%N/A+14.5%$156.65M$1M-2.2810News CoverageShort Interest ↑SPROSpero Therapeutics3.8122 of 5 stars$2.76+10.4%$5.00+81.2%+106.6%$154.31M$28.30M39.43150Short Interest ↑Gap DownHigh Trading Volume Related Companies and Tools Related Companies Alumis Alternatives Editas Medicine Alternatives Aclaris Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Silence Therapeutics Alternatives RAPT Therapeutics Alternatives LifeVantage Alternatives Molecular Partners Alternatives SELLAS Life Sciences Group Alternatives Spero Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
